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Abstract 
Breath analysis holds the promise of a non-invasive technique for the diagnosis of 
diverse respiratory conditions including COPD and lung cancer. Breath contains small 
metabolites that may be putative biomarkers of these conditions. However, the 
discovery of reliable biomarkers is a considerable challenge in the presence of both 
clinical and instrumental confounding factors. Among the latter, instrumental time drifts 
are highly relevant, as since question the short and long-term validity of predictive 
models. In this work we present a methodology to counter instrumental drifts using 
information from interleaved blanks for a case study of GC-MS data from breath 
samples. The proposed method includes feature filtering, and additive, multiplicative 
and multivariate drift corrections, the latter being based on Component Correction. 
Biomarker discovery was based on Genetic Algorithms in a filter configuration using 
Fisher´s ratio computed in the Partial Least Squares – Discriminant Analysis subspace 
as a figure of merit. Using our protocol, we have been able to find nine peaks that 
provide a statistically significant Area under the ROC Curve (AUC) of 0.75 for COPD 
discrimination. The method developed has been successfully validated using blind 
samples in short-term temporal validation. However, in the attempt to use this model for 
patient screening six months later was not successful. This negative result highlights the 
importance of increasing validation rigour when reporting biomarker discovery results.  
  
Page 2 of 48AUTHOR SUBMITTED MANUSCRIPT - JBR-100690.R1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 Ac
ce
pte
d M
a
us
cri
pt
 3 
Introduction 
Volatile biomarker discovery is increasingly gaining attention in the improvement of 
screening, diagnosis, and prognosis in medicine.1 Volatilome is the volatile fraction of 
metabolome,2 which contains all those volatile organic compounds (VOCs) generated 
within an organism. VOCs are organic analytes with a substantial vapour pressure 
(typically less than 300 Da) and their analysis allows monitoring human chemistry and 
health related conditions.3 VOCs reflect metabolic processes that occur in the body and 
which may change with disease. Thus, finding specific VOC fingerprints that are 
characteristic of a pathology is an important field of research.4,5,6 The analysis of 
exhaled breath is a specifically attractive and promising means of access to the 
volatilome, as breath can be obtained non-invasively and contains potentially 
informative VOCs. VOCs can reach the alveoli, cross the alveolar interface and then be 
exhaled by the subject.7,8 
The discovery of new disease markers is based on measuring the global metabolic 
profile of a sample without bias, which is known as untargeted metabolomics or 
metabolic fingerprinting.9 Advanced analytical instrumentation, mainly mass 
spectrometry (MS) and nuclear magnetic resonance (NMR), provides the researchers 
with possibility of examining hundreds or thousands of metabolites in parallel. Gas 
chromatography – mass spectrometry (GC-MS) in particular, is one of the most popular 
and powerful analytical techniques for breath analysis.8  
The comparison of metabolic fingerprints among different experimental groups; namely 
condition and control, can lead to the identification of metabolic patterns that have 
changed due to a disease, and which may be used as a diagnostic tool. Chemometric or 
pattern recognition methods are required to extract information from exhaled breath 
data and discover relevant VOCs.10 However, many data processing techniques are not 
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designed to deal with large amounts of irrelevant or correlated features, which is the 
case with current analytical technologies that are applied to metabolomics. For instance, 
in a review on the statistical analysis of metabolomics data, Vinaixa11 observes a 
number of metabolomics studies (based on Liquid Chromatography-Mass 
Spectrometry, LC-MS) where the number of features ranges between 4000-10000, 
while the number of subjects is always below 30. In other words, from a data-analysis 
perspective, metabolomics data is characterized by high dimensionality and small 
sample counts. Consequently, the ‘Curse of Dimensionality’12 has to be taken into 
account, and data processing methods must be scrutinized in their ability to deal with 
small sample-to-dimensionality ratios.13,14 The inherent difficulty in the analysis of this 
type of data has long-been recognized and methods to deal with it have been proposed 
since the 60s.15 The application of conventional statistical testing is plagued with 
theoretical difficulties,16 and in many cases machine learning approaches are preferred. 
However, the scarcity of examples poses problems with respect to the complexity of 
those predictive models that may be built. Complexity control can be attained through 
regularization or through dimensionality- reduction techniques.13 Some authors 
advocate the use of penalized likelihood estimation.17 One example is the use of the 
Least Absolute Shrinkage and Selection Operator (LASSO) based on L1 penalty in the 
quest for sparse solutions,18 while others propose projection methods, such as Principal 
Component Analysis (PCA)19 or Partial Least Squares-Discriminant Analysis (PLS-
DA).20 However, the use of feature selection methods based on iterative searches and 
optimization procedures, using either wrappers or filters as objective functions is 
perhaps the most popular approach.21 The performance of these methods in high-
dimensionality, small-sample conditions has been analysed previously.22 Among them, 
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Genetic Algorithms (GA) have been used extensively.23,24,25 The combination of GA 
and PLS-DA in metabolomics has been previously reported.26 
 
The application of dimensionality-reduction techniques based on feature selection 
methods is therefore the natural choice.17  
Breath analysis is particularly challenging due to the lack of standards for sampling and 
storage that are employed.27,28,29 As such, researchers prefer to analyse breath samples 
soon after collection. If patient recruitment takes a long time, then analysis may extend 
over several months. In these conditions, instrumental changes, such as 
chromatographic column aging, temperature variations and the effects of contamination 
can shift intensity value measurements over time.30,31,32,33 As computational methods in 
metabolomics rely on a quantitative comparison between metabolite abundances in 
diverse groups, instrumental drift may become an important source of errors. It is 
therefore extremely important to block this potentially confounding factor at the design 
stage, if possible.34 Another inherent difficulty involved in breath analysis is the large 
inter and intra-individual variability of exhaled breath, even among healthy subjects,35 
and the change of VOCs patterns according to food consumption, smoking, gender, age, 
and so forth.36,37 There are definitely several sources of unwanted variance that may act 
as confounding factors, and which can be divided into two types: instrumental (e.g. 
different location, operator, instrument or sampling conditions), and clinical (e.g. 
gender, age, smoking status, comorbidities or treatments).38,29 If some factors cannot be 
controlled with experimental design,39 they must be taken into consideration during data 
analysis.40 
Normalization methods adjust data for biases caused by non-biological conditions or 
unwanted variations.36,41,42 Most adopted normalization methods rely on scaling factors 
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using all the data set (e.g. total sum or norm). However, these methods have been shown 
to adjust data incorrectly, as an increased abundance in some metabolites leads to a 
decrease in other metabolites.43  
Alternatively, internal standards (IS) and quality control (QC) samples are often used 
for the posterior removal of certain systematic errors that maybe platform specific.40 
The internal standards method is based on the addition of known metabolites (in a 
determined amount) to the samples in order to improve quantitative analysis and 
normalize each sample according to their variation. The simplest approach is based on a 
single internal standard and assumes that the variation in sensitivity observed for this 
metabolite is constant across all the analytes. Thus, a multiplicative correction factor 
may be applied. However, it is not clear that the underlying hypothesis can be sustained, 
and therefore the use of multiple internal standards has been proposed, but then the 
selection of the proper normalization method remains an open problem. Application 
examples of normalization methods based on IS have been reported on literature.43,40 
For instance M. Sysi-Aho et al. proposes that the correction factors are a linear function 
of the variation observed for the IS, and he optimizes the coefficients of the model to 
maximize the likelihood of the observed data.32 However, in untargeted studies, the 
metabolites that are to be detected are not known a priori, and therefore the addition of 
numerous IS for detection and to normalize for analytical variation is not practical, 
indeed it would prejudice the integrity of the samples.31 As such, QC are often preferred 
in untargeted metabolomics in order to avoid changing the physical sample and using IS 
that may coelute with metabolites of interest.44 QC samples may be either commercial 
or pooled (i.e., a mixture of equal aliquots from a representative set of the study 
samples). The latter are of special interest, as their measurement contains all those 
metabolites under investigation. Even though pooled QC samples may be relatively 
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easy to prepare for some biofluids, such as urine or plasma,45,46 exhaled breath presents 
inherent complications in terms of sampling and storage, which prevents its use, 
especially in long-term studies. Different signal correction methods rely on QC 
samples,44,47 which can be employed to estimate sample- or feature-based correction 
factors.31 According to previous works,42,48 one of the best normalization methods that 
employs QC samples is Probabilistic Quotient Normalization (PQN).49  
Since machine drifts are frequently observed in chromatography and MS, the 
assessment of reproducibility and repeatability is of utmost importance.50,51 Over the 
last decade, a number of computational algorithms have been applied in order to correct 
instrumental drifts, or batches in data. For instance, ComBat technique was proposed in 
the genomics field and was later also applied in metabolomics, for adjusting data for 
batch effects.52,30 Many methods are based on projection filters. Examples of these 
methods are Component Correction (CC) and Common Principal Component Analysis 
(CPCA). They consist of the estimation of the drift subspace with a reference class or 
the entire data set, respectively, and the subtraction of this subspace from the original 
data.30,53 The dimensionality of the drift subspace should be carefully determined using 
calibration data, in order to avoid valuable information removal. For example, 
Fernández-Albert et al. used Dunn and Silhouette indexes to compare different drift 
correction methods and the dimensionalities of the drift subspace.30 Another example in 
this family is Orthogonal Signal Correction (OSC), which removes the data variance 
that is uncorrelated to the class information.54 Similarly, orthogonal projections to latent 
structures, such as Orthogonal Partial Least Squares algorithms (O-PLS or O2-PLS), 
have also been applied for drift compensation.55,56,57 The existing literature mostly uses 
these methods for predictive models, but not specifically in biomarker discovery, where 
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the impact of instrumental drift on computational biomarker discovery is not yet totally 
understood, and remains an under-studied topic. 
Unfortunately, those studies of biomarker discovery in metabolomics that have been 
undertaken are usually plagued by statistical bias, and involve small sample sizes, 
which lead to very poor reproducibility. This is aggravated by the use of weak 
validation methodologies that mostly consist of internal validation. We believe that only 
external validation (blind samples) can provide further reliability to biomarker 
discoveries. Moreover, an additional temporal validation, undertaken months after the 
model development process has been closed, should be a recommended practise. 
However, in most published literature this long-term validation is missing. If we expect 
that discovered biomarkers can be adapted and be put into clinical use, then their use 
has to be reliable enough to maintain predictive power in a variety of instrumental 
conditions, or even instrument vendors. Reporting long-term validation results would 
allow the discovery of the limitations of current research and speed up further 
investigation into the most promising biomarker discovery studies. 
In this work, methods for the instrumental drift in GC-MS data from exhaled breath are 
proposed and investigated through their application in a practical case. The analysed 
dataset consists of breath samples obtained from patients with lung cancer (LC), chronic 
obstructive pulmonary disease (COPD), and control subjects, in order to discover the 
markers of these diseases. Since this dataset was acquired over a two-year period, the 
correction of instrumental drift in the entire dataset was one of the data analysis 
objectives. The influence of time varying effects requires special attention to the 
application of strict validation procedures, which was an essential part of our workflow. 
We not only used external validation, but also an additional temporal validation in order 
to assess the predictive power of the biomarkers, six months after the end of the model 
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development phase, which is a validation level that is not usually reported in similar 
studies. From a machine-learning standpoint, biomarker discovery may be addressed 
using feature-selection techniques. 
In this quest for putative biomarkers, additional issues, such as potential clinical 
confounders have also been investigated. Finally, biomarker selection and classification 
was applied to the binary problem case of COPD vs. control. 
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Experimental Methods 
Sampling System 
Exhaled breath was collected using the tidal breath sampler (TBS) shown in Figure 1, 
which was and developed by the Department of Biochemistry and Molecular Biology of 
the University of Barcelona.58 It consists of a glass tube with a specific shape that 
allows the collection of tidal exhaled air. The subject breathes into a unidirectional 
Rudolph valve, which allows medical air (22% O2, 78% N2) contained in a Douglas bag 
to pass through his mouth and which then transports the exhaled breath to the glass 
tube. An air pump (FLEX Air Pump 1001) extracts the air from the first section of the 
glass tube and drives it to a sorbent trap that is filled by a fibre comprising 200 mg 
Tenax and 200 mg Unicarb. Between the glass tube and the fibre is a filter made of 
silica gel, to avoid humidity, which distorts mass spectra. In order to avoid breath 
condensation on the walls of the glass, the tube is heated using a long, warmed filament, 
which is wrapped along its length. See Supplementary Material for sampling protocol 
information. 
 
Figure 1. Tidal Breath Sampler. A diagram of the sampling system used to collect 
VOCs from exhaled breath is shown above. 1: Douglas bag with medical air. 2: 
Unidirectional Rudolph valve. 3: Mouthpiece for subject´s breath. 4: Glass tube at high 
temperature. 5: Outlet for the vast majority of air. 6: Outlet for the final part of the 
Page 10 of 48AUTHOR SUBMITTED MANUSCRIPT - JBR-100690.R1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 Ac
ce
pte
d M
an
us
cr
pt
 11 
subject´s exhalation (containing the VOCs from gas exchange). 7: Silica gel filter for 
humidity control. 8: Sorbent trap. 9: Air pump. 10: Air exiting the pump. 
 
GC-MS Analysis 
Samples were injected into the gas chromatograph system using a Unity thermal 
desorption unit for sorbent tubes (Markes). This unit applied a flow of hot carrier gas 
through the fibres contained in the sorbent traps, desorbing the VOCs in its surface and 
carrying them to the GC system (FocusGC, fThermo Scientific). The chromatographic 
column used was a 60 m DB-624 capillary column with an internal diameter of 0.32 
mm and a stationary phase thickness of 1.8 µm. The temperature ramp used to optimize 
the separation and sensitivity of the chromatographic process was: 40 ºC (5 minutes) – 
10 ºC (1 minute) – 180 ºC (1 minute) – 15 ºC (1 minute) – 230 ºC (10 minutes). Once 
eluded from the column at different retention times, the separated compounds were 
injected into the MS (DSQII MS, from ThermoScientific), where they were ionized via 
electron impact and subsequently fragmented. In order to reuse the sorbent traps, once 
desorbed, they were then cleaned to eliminate any possible remaining VOCs, with a 
flow of N2 at 320 ºC for 2 hours, before being closed and stored in vacuum.  
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Dataset and Data Processing Algorithms 
Dataset Description 
The dataset contained four classes or medical groups: control, COPD, LC, and both 
diseases (COPDLC). Standard diagnostic criteria were used for the inclusion of each 
study group. The main exclusion criteria were: (i) Lack of clinical stability; (ii) 
Abnormal non-obstructive forced spirometry results; (iii) Previous history of cancer; 
(iv) Previous history of active inflammatory disease; (v) Treatment with steroids or 
immunomodulators; and, (vi) Data suggesting infectious disease. The protocol was 
submitted and approved by the Human Studies Ethical Committee at Hospital Clinic 
and all patients signed informed consent forms before any procedure was initiated. 
 
The sample collection procedure lasted almost two years (from 20/05/11 to 6/5/13) and 
was divided in two campaigns. The first campaign lasted from 20/05/11 to 7/3/12 and 
was divided into calibration (initial 80%) and short-term external validation set (last 
20% of each class). The second campaign lasted from 10/7/12 to 6/5/13. It is important 
to note that the collection and analysis protocol was identical in both campaigns. The 
purpose of the second campaign was to further validate the results obtained from the 
study carried out in the first campaign. This second campaign served not only to provide 
blind samples, but also to test the stability of the predictive model. It is important to 
note that this stability test is neglected in most studies and validation is internal to the 
same measurement campaign. All model development and optimization, including drift 
counteraction strategies, was undertaken within the calibration set. The number of 
samples included in the study is summarized in Table 1.  
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Data subsets Control COPD COPDLC LC 
Calibration 15 22 15 10 
Short-term 
validation 
6 7 4 2 
Long-term 
validation 
6 5 5 - 
Total 27 34 24 12 
 
 
Table 1. Data Set Overview. The number of samples of each class is reported by data 
subsets (calibration, short-term, and long-term validation) and also the total number. 
COPD: Chronic Obstructive Pulmonary Disease, LC: Lung Cancer, COPDLC: COPD 
and LC. 
 
The metadata of the patients was also available, including sex, age, weight, height, 
smoking status, functional respiratory results (forced expiratory volume and forced vital 
capacity) and haematology tests, current treatments or drugs that the patients were 
taking, comorbidities (e.g. hypertension, asthma, diabetes), and diagnostics of the 
studied disease. 
Apart from the patient samples, two types of spectra blanks were available: (i) 7 fibre 
blanks (GC-MS analysis of new sorbent traps that were not previously used for any 
sample), and (ii) 49 sample blanks (GC-MS analysis of sorbent traps in each day of 
measurement). Fibre blanks are used to assess the existence of specific peaks due to the 
presence of fibre, whereas sample blanks serve to assess the potential contamination of 
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the system. Even if no sample is injected, a signal can be obtained, due to the VOCs 
trapped in the column, while sample blanks provide quantification. 
Data Pre-processing 
Data pre-processing was performed with MZmine259 software. Peak detection was based 
on the Noise Amplitude algorithm. In this algorithm, intensity range is specified by the 
user and the algorithm automatically locates the where the noisy baseline is 
concentrated, and establishes the baseline level at this level. A peak is recognised when 
the chromatographic signal is registered above the noise level during a certain time 
span. A smoothed second derivative, Savitzky-Golay digital filter is then used to detect 
the borders of the peaks. After detection, peaks were aligned using the RANSAC 
aligner. Here the retention time tolerance was 1 minute, with an m/z tolerance of 0.4. 
The number of iterations was automatically determined by the software. MZmine also 
provides tools for isotopic peak grouping and gap filling in the event of missing 
values.60 After MZmine pre-processing, 3049 peaks with an associated intensity were 
obtained. Each peak was identified by its mass to charge ratio (m/z) and retention time 
(RT). The area under the peaks was computed in order to obtain the data matrix. Since 
there were peaks with the same RT (differences less than the GC resolution, 0.1 min) 
and large correlation (Pearson correlation r > 0.9) between them, they were considered 
to be part of the same original compounds. By clustering these peaks and removing near 
zero variance features, the dimensionality of the data was reduced from 3049 to 1749 
features. In total, 1297 features were removed by peak clustering, while 3 were 
removed, as they had near zero variance. Finally, 1793 features (peak areas) were 
retained.  
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Rank Products 
Rank Products (RP) is a feature-selection algorithm proposed by Breitling that is used 
to find the differentially expressed genes.61 It is an intuitive method that was designed to 
rank genes according to the up or down-regulation magnitude in all microarray 
replicates. If one variable is highly ranked in many replicates, greater confidence can be 
given to the consistence of the results. The Rank Product method has been widely 
applied in other domains, such as proteomics and metabolomics.62,63 RP provides an 
estimator that may be computed for each feature. It is important to compare the obtained 
RP value with the sampling distribution under the null hypothesis that the differential 
expression values are identically distributed. In order to do this, we have used the 
permutation sampling procedure originally proposed by Breitling, using 100 iterations. 
In order to calculate the RP estimator, the RankProd library in R was used.64 For each 
feature f in k replicates, each containing ni features, the rank product is calculated as: 
RPf
up
=  ∏ (
ri,f
ni
k
i =1 )             (Eq.1) 
Where 𝑟𝑖,𝑓 is the ranking position of the feature f in the replicate i. 
Probabilistic Quotient Normalization 
PQN method estimates a gain for every sample by using a reference spectrum.49,42 This 
reference spectrum is normally a Quality Control (QC) sample made up of a pooled mix 
of equal aliquots from a representative set of the study samples. The median of the ratio 
between the sample and reference spectrum is computed and serves as a quotient to 
compensate for variations.  
𝑥𝑖
𝑃𝑄𝑁 = [
𝑥𝑖,1
median(
𝑥𝑖,1
𝑥𝑟𝑒𝑓,1
)
, … ,
𝑥𝑖,𝑛
median(
𝑥𝑖,𝑛
𝑥𝑟𝑒𝑓,𝑛
)
]     (Eq.2)  
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for sample i with features xi,j - with j ranging from 1 to n. xi
PQN is the corrected feature 
vector for sample i and xref
 is the reference spectrum with features xref,j. Note that the 
median is calculated across samples for each feature. The challenges associated with 
normalization techniques in metabolomics are discussed by Filzmoser.42 
 
Component Correction 
CC assumes that the variance introduced by the drift is explained with one or more 
principal components (PCs) of a given reference class.30 PCs that define the drift 
subspace are subtracted from the original data.54 
𝑋𝑐 = 𝑋 − (𝑋 · 𝑃)𝑃
𝑇         (eq. 3) 
where Xc is the corrected data, X is the original data matrix, and P are the loadings (or 
principal components) spanning the drift subspace.  
Genetic Algorithms 
Genetic Algorithms (GA) are a feature-selection technique based on the survival of the 
fittest individual.65 An individual is defined as a subset of selected features (binary 
vector with 1s and 0s, which are taken to mean selected or not selected, respectively). 
GA initializes a population of many individuals and evaluates their performance 
according to a predefined criterion (fitness function). The fittest individuals are selected 
and used to generate a new population through crossover; either by mating and/or by 
mutation The chosen figure of merit has been the Generalized Fisher Ratio,66 computed 
in latent variable space using internal validation samples. This goal function is more 
sensitive than the classification rate (CR), and it is known that filters are less 
computationally expensive than wrappers. 
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 The general framework was obtained from GA library.67 Readers interested in an 
overview of feature selection techniques for omics readers are referred to Gromski et 
al.68 and Saeys et al. 21 and the examples therein.  
 
Partial Least Squares – Discriminant Analysis 
Partial Least Squares – Discriminant Analysis (PLS-DA) can be understood as a PLS 
regression between a data matrix, X, and a categorical one, Y.69,70 X contains the set of 
predictors, whereas Y consists of labels or responses, in this case a binary vector. PLS 
regression is based on an iterative process to define a new subspace of latent variables 
(LV).71 In order to define it, PLS considers a compromise between maximum variance 
modelling X and maximum correlation with Y. Different algorithms are used to compute 
PLS, in this work, the kernel PLS algorithm implemented in pls R package has been 
applied.72 The use of PLS-DA for metabolomics has been covered extensively in the 
literature.73,74  
 
Random Forests 
Random Forests (RF)75 are machine-learning techniques often used for omics data 
analysis for the purposes of classification.76 RF is an ensemble classifier that consists of 
multiple decision trees, each of which is built using a subset of features and data 
samples. They also possess an additional advantage in that they deliver an automatic 
ranking of variable importance that can be used for biomarker discovery.77 Here the 
RandomForest R package was used.  
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Data Analysis Protocol 
Instrumental drift correction 
Data was inspected by PCA in order to determine the effect of time. Blanks were then 
used for in order to filter out noisy features. To this end, two strategies were adopted: (i) 
Non-parametric Wilcoxon test for fibre blanks, and (ii) RP for sample blanks. The one-
sided Wilcoxon test78 was used to check which features had a median distribution of 
intensity values that were higher in sample than in fibre blanks. Metabolites that were 
equally or less abundant in sample than in fibre blanks were considered as 
contamination, as they were likely to be non-informative, and as a result, they were 
discarded. The testing of this hypothesis was performed for all classes taken together, 
versus fibre blanks, due to the availability of only 7 fibre blanks. The RP method, 
however, was applied in order to compare the metabolic profiles of each class versus the 
sample blanks, for which a larger sample of 49 blanks was available. Therefore, four 
contrasts were defined in order to assess which features possessed more intensity in any 
of the classes than in sample blanks. The consideration of all samples (control, COPD, 
COPD-LC, and LC) in the same group in order to undertake the contrast versus sample 
blanks may have resulted in peaks that were highly abundant only in one class being 
removed. Thus, in order to avoid removing the relevant variables, all those variables 
that were more present in any patient group than in blanks were retained. 
Contamination and memory effects in the conserved ion fragments were assumed to be 
additive noise that could be corrected. The intensity measured in the previous blank was 
then subtracted from the intensity of an ion fragment from a sample.79,80 The possibility 
of gain variations in time was explored beyond the additional correction of potential 
instrument contamination. A normalization strategy inspired in PQN was introduced, 
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which was aimed at removing the so-called size-effect.42 The major difference between 
PQN and the applied method is that the gain variations were estimated with sample 
blanks. The multiplicative factor of a sample is given by the median of the ratio 
between the reference blank and a blank acquired previous to sampling. The reference 
blank chosen was one of 13/12/11, as intensity fluctuations within that time period were 
limited. The expression that encompasses both the removal of sample blanks and 
multiplicative correction is the following. 
𝑥𝑖𝐶 =  median (
𝑥𝐵𝑙𝑎𝑛𝑘 𝑟𝑒𝑓
𝑥𝐵𝑙𝑎𝑛𝑘 𝑖
) (𝑥𝑖 −  𝑥𝐵𝑙𝑎𝑛𝑘 𝑖)  (Eq. 4) 
Where xi is a sample, xiC is the corrected sample, xBlank i is the previous blank to the 
sample, and xBlank ref is the blank of reference in the middle of the study (13/11/11). 
Moreover, CC was applied using sample blanks as the reference class to estimate drift 
subspace. Two figures of merit were considered at this stage, in order to optimize the 
number of PCs to be eliminated: the Pearson Correlation Coefficient of data with time,81 
and the Hotelling T2 Statistic, which is used to estimate the distance between classes.82  
Potential Clinical Confounders 
Then hypothesis testing was used to check if controlled clinical variables were equally 
distributed between the defined groups, or if they acted as confounding factors. Tests 
were carried out to compare classes two-by-two. The Chi-squared test (or Fisher´s Test, 
if at least one expected frequency was lower than 5) was applied to the factorial 
variables; sex, smoking status, presence of hypertension, and presence of diabetes.83 For 
the numerical variables; age and body mass index (BMI), the non-parametric Wilcoxon 
Test was used. 
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Biomarker Discovery 
Pre-processing included outlier detection using the Mahalanobis distance, centring and 
auto-scaling to unit variance. Biomarker candidates were selected by GA, Fisher´s ratio 
computed in PLS-DA latent variable space being the figure of merit to maximize.84 
Some measures were adopted following the recommendations of R. Leardi and A. 
Lupiáñez González to ensure a proper choice of selected features that do not lead to 
model overfitting.85 One of them was to limit the number of GA iterations according to 
the fitness saturation of the best individual. Moreover, in order to avoid the exploration 
of only a reduced part of the search domain, different GA runs with random 
initialization were performed, and feature selection frequencies were computed. The 
entropy of this feature selection frequency distribution was introduced as a stopping 
criterion for GA.86 The saturation of entropy was related to a stable feature selection 
that does not change with more runs, i.e., more executions do not lead to an increase in 
information. The frequency distribution of a random selection (simulation of random 
selection 1,000 times) was computed, and the final subset consisted of those features 
selected in more runs than would be expected by chance. A PLS-DA model was built 
with this feature subset, and the number of latent variables (LV) was optimized using a 
cross-validation in the calibration set. External validation of the model was carried out 
using short-term and long-term validation data, and permutation tests of 10,000 
iterations were employed to check if the results were statistically significant as 
compared to a random classification. 
At this point it is important to note that the data processing workflow implemented that 
includes feature selection using GA provides only fragment candidates. Mass spectra 
matching is needed to obtain analytes from fragment candidates. The NIST Mass 
Spectral Search Program 2.3 was used for this purpose. 
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For reasons of comparison, the use of feature selection based on PLS-DA and RF 
models was also explored and compared to the proposed methodology of GA and PLS-
DA. On the one hand, the Variable Importance in Projection (VIP) was applied to the 
global PLS-DA model (without GA).87 Moreover, two variable importance measures 
were used for the RF model. The first was the total decrease in node impurities from 
splitting on the variable, averaged over all trees (for classification, the Gini index). The 
second measure of importance was based on the error rate in classification for out-of-
bag data, when variable predictors are permuted and averaged over all trees.  
 
Results and Discussion 
Instrumental Drift Correction 
Data Inspection: Unsupervised Exploration of Time Effects in Uncorrected Data 
 
For a better understanding of high dimensional data, it is convenient to visually inspect 
the projection to subspace that capture maximum variance using PCA. Figure 2 shows 
PCA score plots for calibration and short-term validation subsets. Figure 2a is coloured 
according to date of acquisition and reveals a clear relationship between the maximum 
variance directions in the data set and time. The two observed clusters are not due to the 
medical conditions under study, as it can be seen from Figure 2b, but consist of 
unwanted variance that should be removed, since it seems to be causing a separation 
between samples collected at various times. Therefore, through unsupervised data 
exploration, an instrumental signal drift explaining a considerable variance of the 
dataset was detected. However, it was not possible to specify a particular date in which 
the instrument changed within the calibration subset. 
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Figure 2. PCA score plot of calibration data. Score plots of PC1 and PC2 are shown 
(a) colouring samples (using a two-colour gradient) according to the date of acquisition 
(i.e., number of days since the first data acquisition of the study), and (b) colouring 
samples according to the class under study. 
 
Feature filtering 
In this section, we set up procedures to select features that are informative about the 
breath composition of the subjects, while rejecting sample contamination due to the 
absorbent fibre used or memory effects in the instrument. In order to do so, we took 
advantage of the two types of blanks were available in this study, fibre and sample 
blanks. They provide a measurement of baseline noise due to peaks caused respectively 
by the fibre or memory in the instrument in each day of acquisition. These data were 
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employed to reduce the dimensionality of the dataset by removing noisy features. We 
would like to emphasize that this feature filtering was exclusively done using 
calibration data. 
First, a univariate Wilcoxon test indicated that 1693 of 1752 features had significantly 
higher intensity profile in patients’ samples than in the analysis of fibre blanks (new 
sorbent traps without samples). For the rest, the null hypothesis was accepted, and 59 
features were removed from the data. In this step, features that fulfilled the null 
hypothesis were filtered out. With the intention of removing only those features that 
clearly belong to the blanks, no multiple testing correction was implemented. Multiple 
correction testing is stricter in order to identify samples that do not conform to the null 
hypothesis but, in this case, the aim was to identify features that clearly do conform to 
the null hypothesis. 
Second, an alternative use of the RP method, which is often utilized as a univariate 
feature selection for biomarker discovery in genomics, was proposed. Instead of 
comparing classes under study among them to find putative biomarkers, binary 
contrasts of each class vs. sample blanks were computed. Features can have larger value 
distributions in one or more classes with respect to sample blanks, and RP results 
indicated that 79 features had higher intensity in one study class, 66 in two, 84 in three, 
and 243 in the four classes with respect to blanks. With this RP strategy, dimensionality 
was further reduced, from 1693 to 472 features. Figure 3 shows that eliminated features 
mainly correspond to compounds eluting at longer RTs, which might be related to 
compounds of lower volatility, higher molecular weight, or more affinity with the 
chromatographic column. Since these RTs were shown to contribute more in the PCA 
loadings of the initial data, they largely hide the effect of lower intensity features. As a 
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consequence, feature filtering did not only reduce computational cost, but probably 
improved the power in identifying real biomarkers.  
 
Figure 3. Data filtering based on sample blanks data. Density estimations are shown 
for the retention times of the conserved (red) and removed (blue) features using sample 
blanks data. 
The score plot in Figure 4 indicates that despite this filtering, the data still showed a 
temporal separation of samples. In this figure, long-term validation samples were also 
added to show how they differ from the other data points. When the long-term 
validation subset is considered, the first PC reflects the separation between them and the 
rest of samples, and the second PC is the one which reveals the two previously observed 
clusters.  
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Figure 4. PCA score plot of all the data of the study after filtering. Score plots of 
PC1 and PC2 for all the samples (calibration, short-term, and long-term blinds) after 
data filtering using blanks data (i.e., data set with 472 features). 
 
Figure 5 represents the first PC scores with respect to the date of acquisition and also 
shows that long-term data are remarkably different from the samples collected during 
the first year of the study. Acquisition of the last data subset was over a long period of 
time, which results in different batches even within long-term validation samples. 
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Figure 5. Change of PC1 scores over time. Score plots of PC1 are reported for all the 
samples with respect to the date of acquisition for filtered data (i.e., 472 features). 
 
Even though in this study there were no QC samples, inspection of the changes in 
sample blanks allowed us to learn about time effects. Our initial observation was that 
sample blanks shared a lot of common fragments. On this basis, additive and 
multiplicative corrections were proposed. 
Additive and multiplicative corrections 
We have already mentioned that ion fragments with the same amplitude in the real 
samples and in the blanks were discarded. Beyond this additive correction, sample 
blanks showed contamination and memory effects in the conserved features. Therefore, 
each sample had the intensity values of the previous blank subtracted from its 
Long%term
validation set
Training1set Short%term
validation set
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intensities. Even after additive correction, large variations in the intensity of the 
chromatograms were still observed and the possibility of gain variations over time was 
explored. Figure 6 shows boxplots of the intensity ratios between a reference blank in 
the middle of the study and the rest. While ratios among fragments showed some 
scatter, there was a clear central value that differed across days. This effect leads us to 
the hypothesis of instabilities of sensitivity over time. In order to compensate for this, a 
gain correction was estimated through the median of the ratios across ion fragments. 
Figure 6 reports a clear pattern for a change in the gain over time. There was a sharp 
variation in the gain on a particular date (10/07/12), which separates the group of the 
short-term and long-term validation data.  
In order to compensate for the observed time effect, the multiplicative correction 
method described by Equation 4 was used—this assumes that there is a uniform gain 
variation across features for each sample. Additionally, an underlying hypothesis for 
this correction is that the estimated gain variation with sample blanks is the same for all 
the samples measured in this particular day. This normalization approach to correct the 
multiplicative effect is inspired by PQN, but using data from blanks as reference. 
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Figure 6. Intensity ratios of sample blanks. The ratios between a reference blank 
(13/12/11) and the rest of blanks are shown for each date of acquisition. Note that the 
time scale in x-axis is not uniform. 
 
The application of the former normalization method minimized the effect of gain 
variations, and the long-term validation data was especially effective in diminishing 
their variability with respect to the rest of samples. However, temporal variation might 
also be correlated among features and, consequently, some privileged drift directions 
may exit. To account for such multivariate correction of instrumental drift, CC was 
implemented. 
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Component correction 
For CC, sample blanks were chosen as the reference class. Variance in the reference 
class was modelled with PCA. The technique assumes that the drift subspace was 
shared between the blanks and the samples. This drift subspace is spanned by a number 
of principal components estimated from the PCA of the blanks. Since the removed 
component(s) might be explaining not merely the drift, but also biological differences 
under study, it is important to optimize the number of removed components and making 
an appropriate trade-off is essential. Correlation of data with time decreased with 
respect to the original data when removing the first PCs of sample blanks, so CC 
appeared to diminish the temporal dependence. Moreover, the use of the two-sample 
Hotelling T2 statistic was proposed to estimate distance between classes. Results 
showed that removing the first PC of the blanks in the original data matrix maximizes 
the Hotelling T2 statistic. Therefore, one PC was shown to minimize correlation with 
time and maximize distance between groups in binary contrasts (as measured by the 
Hotelling statistic).  
Figure 7 shows the PCA score plot for data corrected by the methodology we have 
outlined. The two “date of acquisition” data clusters vanished after the correction was 
applied. In addition, long-term validation samples are closer to the other data points. 
Visually there has been a great improvement, but the correlation of the data with time 
was also computed to compare the methods, in particular the four cases explained above 
i.e. feature filtering (FF), feature filtering plus additive and multiplicative correction 
(AM), feature filtering plus CC, and the combination of all the methods (FF+AM+CC). 
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Figure 7. PCA score plot of all data after multiplicative and Component 
Correction. Score plots of PC1 and PC 2 are reported after multiplicative and 
component correction based on sample blanks data. 
 
 
 Figure 8 shows that correlation with time substantially diminished when applying the 
three strategies: feature filtering, additive and multiplicative correction, and CC. 
Therefore, blanks were successfully used to diminish the significant instrumental drift 
present in the GC-MS data. 
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Figure 8. Comparison of applied corrections. The correlation with time (r coefficient) 
is shown for original data (O), data after feature filtering (FF), FF plus additive and 
multiplicative corrections (AM), FF plus component correction (CC), and the 
combination of the three strategies, FF+AM+CC. 
 
Potential clinical confounders 
The clinical variables, sex, age, BMI, smoking status, and the two more frequent 
comorbidities in the dataset, hypertension and diabetes mellitus II, were tested for 
different distributions between study groups. These factors were equally distributed 
between the study groups COPD and control (with 95% confidence). However, there 
were potential confounding factors for the cases of COPDLC (hypertension, age, and 
smoking status) and LC (hypertension). 
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Biomarker discovery 
LC and COPD are complex diseases; indeed, both are a family of condition subtypes 
and COPD can be an indirect warning of LC. Hence, identification of VOCs signatures 
which allow proper classification of all condition subtypes is a real challenge, especially 
with insufficient data. Additionally, the consideration of clinical confounders in the 
final model complicates biomarker discovery even further. Due to these difficulties, the 
present study has corrected instrumental drift for the complete data set, but has focused 
on the case of COPD for the biomarker discovery stage. COPD intensity profiles were 
compared with those of the control group. This is the condition-control binary 
classification problem but with more samples available (15 for control, after eliminating 
3 outliers, and 23 for COPD in the calibration set), and clinical confounders were not 
found. 
Biomarker selection 
Our biomarker selection strategy aimed at finding a small subset of features that may 
discriminate the two classes, in contrast to other strategies that identify volatile 
fingerprints with several tens or even hundreds of compounds. The discrimination of 
disease by a small subset of variables opens the possibility of further development of 
specific sensor kits for point of care, or clinical applications after biomarker 
identification. 
The search technique based on GA looked for the features that maximize the distance 
between the classes in the PLS-DA subspace. The selection reached the entropy 
saturation criterion after 35 GA runs. Figure 9 reports the frequency of selection of the 
features after these 35 runs. The hypothesis of this approach is that combinations of 
features that exhibit random correlations tend to be selected less often than real 
discriminant features after some trials. Figure 9 shows that nine features were 
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systematically chosen by the algorithm. Hence, they were assumed to contain class 
discriminant information and constituted the subset of putative biomarkers. 
 
Figure 9. GA selection. Frequency of selection for every feature after 35 runs of the 
GA. Features above the threshold were ultimately selected, while features below the 
threshold were selected as often as would be expected at a random.  
Metabolite identification 
As we have already mentioned, the methodology implemented provides only fragments, 
or groups of fragments, that are characterized by an RT and a, m/z. To identify the 
metabolites, the correlation threshold for fragment grouping, which initially was set to 
0.9, was decreased. By decreasing this threshold to 0.6 for fragments appearing at the 
same RT (with a window of 12 seconds), more complete mass spectra were obtained, 
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which allowed the identification of three putative biomarkers. A fourth set of fragments 
did not match any candidate compound from the NIST library.  
(i) Isoprene. This compound appears both in healthy and COPD subjects. Isoprene is a 
major metabolite in the breath. It has been mentioned as a product of lipid peroxidation 
and previous studies have linked it to cholesterol metabolism.88 This compound has 
been proposed as biomarker for COPD in previous studies5 and has been detected in 
breath associated with other respiratory diseases,89 including lung cancer.90 The utility 
of isoprene as biomarker has been reviewed by Salerno-Kennedy and Cashman.91  
(ii) Succinic Acid (Succinate). Succinate in living organism has many roles as a 
metabolic intermediate and as a signal of metabolic state at the cellular level.92 It is 
generated in the mitochondria through the Krebs cycle. Succinate has been proposed as 
a metabolic signal for inflammation,93 and has been found at an increased level in 
inflammatory bowel disease and colitis.93 
(iii) Pentamethylene sulphide. This compound appears in diverse patents as related to 
medication of COPD as a chymase inhibitor94,95 and also in the formulation of anti-
inflammatory agents.96 Consequently, we suspect that this is not a biogenic compound, 
and may be related to the patients’ medication. 
The ranking of fragments provided by VIP in PLS-DA global model, and the feature 
importance provided by RF, were also compared. We note that the models were much 
less sparse than the ones obtained after our GA feature selection. Particularly for VIP in 
PLS-DA, there were many fragments providing similar values. There was not a good 
matching between the fragments selected by GA, and the ones ranked higher in VIP. On 
the other hand, RF gave a very high (top five positions) ranking to fragments related to 
Isoprene, but the rest of fragments selected by GA were medium-ranked by RF.  
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Predictive modelling: Assessment of accuracy in short-term external validation 
Calibration data were used to assess model complexity assessment, both feature 
selection and optimization of the number of LV. Internal cross-validation determined 
that LV=2 was the optimum hyperparameter for a PLS-DA classifier with the selected 
features. A final PLS-DA model was built with all the calibration data, in order to 
estimate its predictive performance when classifying new samples as control or COPD. 
Figure 10 shows the PLS-DA score plot for control and COPD classification, including 
calibration and short-term validation subsets. Control and COPD groups have 
distributions that are slightly separated. The first LV gives two density distributions 
with a certain overlap and the inclusion of the second LV in the model provides a small 
increment in the distance between classes. For short-term validation data, the model 
correctly classified 77% of the samples (CR=77%) and had an Area Under the ROC 
Curve (AUC) of 0.75. Sensitivity was 100%, i.e., all patients with the disease had a 
positive result, whereas the specificity was lower, 50%. Obviously, the trade-off 
between sensitivity and specificity can be adjusted by proper selection of the classifier 
output threshold. Moreover, permutation tests for CR and AUC distributions gave p-
values of 0.015 and 0.029, respectively, which are statistically significant. 
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Figure 10. PLS-DA scores. LV1 and LV2 scores for calibration and short-term 
validation data subsets of control and COPD groups are reported. 
 
Results were compared to other standard classifiers in metabolomics, namely: (i) PLS-
DA on the corrected data without any feature selection using GA and (ii) RF. For PLS-
DA, internal validation provided a model with five latent variables with a classification 
in the short-term external validation which resulted in an accuracy of CR=0.73±0.13 
and an AUC=0.74. Maximum accuracy resulted in a sensitivity of 100%, but a poor 
specificity of 33%. For RF, the same level of accuracy CR=0.69±0.13 was reached, but 
with a poorer AUC of 0.60. These results were achieved with an optimum number of 
variables (mtry in the RandomForest Package) of 25. 
 
Model  CR Sensitivity Specificity AUC 
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PLS-DA with GA 77±12% 100% 50% 0.75 
Random Forest 69±13% 100% 33% 0.60 
PLS-DA  73±13% 100% 40% 0.70 
Table 2: Predictive model performance in short-term external validation. 
Table 2 shows that all models show a moderate prediction capability, despite the drift in 
the dataset. However, there is clear evidence that, after feature selection, the PLS-DA 
model achieves a higher accuracy, and has the added advantage of providing 
parsimonious models involving a reduced number of biomarkers. 
 
Predictive modelling: Assessment of accuracy in long-term external validation 
One of the objectives of the present investigation is to improve the validation of the 
predictive models, and the biomarkers involved in the prediction of the subject 
conditions. Unfortunately, most published works disregard this step, and present the 
results with internal validation or external validation data extracted from the same 
measurement regime. When these external validation data (blind samples), are time 
interleaved with calibration samples, the time effects do not play a role since, the model 
‘knows’ about the future changes in the dataset. However, in the quest for the maximum 
reliability of the chosen biomarkers, the predictive models should, in the future, be able 
to deliver accurate classification of the calibration. In other words, the model should be 
resilient to instrumental or operator changes.  
Results for the long-term validation of the PLS-DA model with the selected biomarkers 
were equivalent to a random classification (CR=55% with a p-value of 0.726). 
Therefore, the built model had a certain degree of predictive ability in the near future, 
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but this did not hold for samples acquired during the second year of the study. 
Instrumental signal drift caused considerable changes on intensity profiles, chiefly 
during long-term validation samples acquisition, making these samples fall outside the 
applicability domain of the model. This loss of predictive power was also observed for 
PLS-DA without feature selection (CR=45%), and for the RF (CR=36%). These results 
show that, on many occasions, instrumental drift called the final application of the 
selected biomarkers into question. More emphasis on long-term validation of results and 
further research on instrumental drift correction are required.  
Conclusions 
We do not yet completely understand how instrumental drift affects biomarker 
discovery studies. The presence of, inter alia, column aging, temperature variations, or 
maintenance operations causes signal drift and hinders the development of models with 
long-term predictive power. This raises a dilemma for biomarker discovery studies: 
analysing more samples leads to the risk of there being more instrumental drift in the 
signals, but a small sample size may not be statistically robust. This is particularly 
relevant for breath analysis, since standardized procedures for the storage of breath 
samples over a long timescale, or for the use of pooled QC samples, simply do not exist. 
In the present study, a GC-MS dataset was obtained from exhaled breath samples and a 
posterior analysis conducted. We have shown how the instrumental drift problem can be 
counteracted in one specific biomarker discovery study. For this particular study, we 
have proposed data processing techniques to minimize instrumental drift using 
information from blanks. In summary, the methodology consisted of using such data for 
feature filtering and removal, a multiplicative correction to compensate for the 
estimated instrumental gain variations in each spectrum, and CC to account for a drift 
subspace correlated among features. This combination of techniques was successfully 
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applied and considerably diminished the correlation of the data with time. It is 
important to be aware that a complete removal of instrumental drift might also eliminate 
discriminant information. Therefore, signal drift compensation is a trade-off between 
removing an unwanted source of variance, and losing the variability of interest. As far 
as we know, RP have not been previously applied in this context of feature filtering, 
since it is generally used for condition vs. control instead of condition/control vs. 
blanks. We also proposed two figures of merit for the choice of the number of PCs to be 
extracted in CC: correlation with time (minimization) and the Hotelling T2 statistic 
(maximization).  
In addition, the combination of a feature selection strategy based on GA, and a PLS-DA 
model, allowed us to classify short-term validation samples in COPD or control classes 
with an accuracy of 77% and an AUC of 0.75, both these magnitudes being statistically 
significant under a permutations test. These results were slightly better than competing 
algorithms such as PLS-DA without GA, and RF.  
 
While the methodology implemented is sufficient to preserve model accuracy in 
external short-term validation, the model could not extrapolate and satisfactorily predict 
long-term test samples which, due to instrumental variations, fall outside its domain of 
applicability. In other words, the methods implemented were not capable of predicting 
the instrumental variations over a longer time horizon.  
In conclusion, we note that instrumental drift entails substantial difficulties in building 
models that are nonlocal in time. The predictive models obtained are unduly sensitive to 
instrumental conditions and in consequence are not robust enough for use in the field. 
We encourage other researchers to devise additional validation levels to improve 
research reproducibility. 
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